Αρχική World News EMA Recommends Granting a Marketing Authorisation for Relacorilant World News EMA Recommends Granting a Marketing Authorisation for Relacorilant Από Ogkologos - 2 Οκτωβρίου, 2026 519 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with epithelial ovarian, Fallopian tube or primary peritoneal cancer Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Diving into our role in 50 top cancer drugs 9 Φεβρουαρίου, 2022 Woman Dances Through Chemo Sessions, Emphasizes Importances of Being ‘Joyful’ 4 Μαρτίου, 2021 FDA Approves Device for Treatment of Osteoid Osteoma in the Extremities 1 Δεκεμβρίου, 2020 Zenocutuzumab Shows Efficacy in Patients with Advanced NRG1 Fusion-positive Cancers 19 Φεβρουαρίου, 2025 Φόρτωση περισσοτέρων HOT NEWS Active Surveillance for Low-Risk Prostate Cancer Continues to Rise EMA Recommends Granting a Conditional Marketing Authorisation for Mosunetuzumab Targeting CLDN18.2 with Zolbetuximab Prolongs Survival When Combined with mFOLFOX6 in... Piecing together the puzzle: Antibiotics, the microbiome and bowel cancer
